Test Price
2,300 AED✅ Home Collection Available
Genetic Cardiovascular Risk Mapping & Polygenic Stratification – DHA-Licensed Genomic Analysis
Executive Summary & Core Metrics
Genetic Mapping for Cardiovascular Disorders is a high-resolution genomic screening test that analyzes single nucleotide polymorphisms and chromosomal copy number variations associated with inherited cardiac conditions including cardiomyopathies, arrhythmogenic disorders, and familial hyperlipidemias. This panel delivers clinically actionable insights for cardiologists, sports scientists, and precision-medicine researchers seeking to identify latent cardiovascular risk before phenotypic manifestation. The analysis is performed at DNA Labs UAE under DHA Facility License 1143, located in Dubai Healthcare City.
Diagnostic Accuracy
99.9%
ISO-Accredited Microarray Processing
Sample Collection
VIP Mobile Phlebotomy
Temperature-Controlled Cold-Chain Logistics, 8 AM – 11 PM Daily
Post-Test Support
Telephonic Genetic Counseling
Interpretation by DHA-Licensed Medical Geneticist
Insurance Verification
Direct Billing Support
WhatsApp: +971 54 548 8731
Test Overview & Methodology
This genomic panel employs high-density single nucleotide polymorphism genotyping via a chromosomal microarray platform to detect genome-wide SNPs and copy number variations across all 22 autosomes and the X chromosome at clinically validated cardiovascular risk loci. Confirmatory analysis uses liquid chromatography-tandem mass spectrometry for targeted validation of metabolically significant variants where indicated. The turnaround time is eight weeks, reflecting the depth of bioinformatic annotation against ClinVar and gnomAD databases, followed by comprehensive clinical report generation.
| Parameter | Our Test — Chromosomal Microarray + SNP Genotyping | Traditional Single-Gene Sequencing | Standard Lipid Panel Only |
|---|---|---|---|
| Genomic Coverage | Genome-wide SNPs + CNVs across all known cardiovascular loci | Limited to one or few targeted genes | No genetic data; biochemical phenotype only |
| Methodology | High-Density SNP Microarray + LC-MS/MS Validation | Sanger Sequencing / NGS Panel | Enzymatic Colorimetric / Turbidimetric |
| Turnaround Time | 8 Weeks (Comprehensive Analysis & Clinical Annotation) | 4–6 Weeks | Same Day |
| Clinical Utility | Predictive, Diagnostic & Prognostic — Polygenic Risk Scoring | Diagnostic for monogenic disorders only | Screening only; no genetic risk stratification |
| Price (UAE) | 2,300 AED | 1,500–4,000 AED (per gene) | 150–300 AED |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh — Consultant Medical Genetics, DHA Registration ID: 9294403
"Genetic mapping does not replace clinical judgment — it empowers it. Every result from this cardiovascular genomic panel must be interpreted within the full context of personal and family history, physical examination, and complementary investigations such as echocardiography and lipid profiling. These insights can transform patient outcomes when used responsibly. However, a negative genetic report does not eliminate cardiovascular risk, and a positive finding requires thoughtful, evidence-based clinical correlation before any intervention."
Pre-Test Advisory — Medication & Supplement Awareness
Important Notice for Patients
Inform your phlebotomist of all current medications, including anticoagulants, antiplatelet agents, and high-dose omega-3 fatty acid supplements. While these do not invalidate genetic testing, they may affect sample integrity for any concurrent biochemical analyses. No medication should be discontinued without explicit physician approval. Do not adjust, initiate, or stop any prescribed cardiovascular therapy based solely on genetic mapping results. Always consult your treating cardiologist before making changes to your medication regimen.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed with Home Collection If:
- Patient is currently hospitalized or in an acute care setting.
- Active febrile illness with temperature exceeding 38.5°C within the last 48 hours.
- Known active hematological malignancy or recent bone marrow transplant (within 90 days).
- Patient is a minor under 18 years without a legally authorized guardian's signed consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Incomplete or unsigned Genome Mapping Consent Form (Form 26).
- Recent whole blood transfusion within 4 weeks — may cause chimerism artifacts.
Emergency Red Flags — Seek Immediate Medical Attention If You Experience:
- Chest pain, pressure, or discomfort radiating to the arm, jaw, or back.
- Syncope or near-syncope, especially during exertion.
- Palpitations accompanied by shortness of breath or dizziness.
- Unexplained dyspnea, orthopnea, or paroxysmal nocturnal dyspnea.
- Family history of sudden cardiac death under age 50 — do not wait for genetic results.
If you experience any of these symptoms, call 998 (UAE Ambulance) or proceed to the nearest Emergency Department immediately. Genetic testing is an elective preventive tool and is not appropriate during acute clinical events.
Patient FAQ & Clinical Guidance
1. What is genetic mapping for cardiovascular disorders and who should consider it?
Genetic mapping for cardiovascular disorders is a comprehensive DNA-based screening test that identifies inherited gene variants linked to heart muscle diseases, electrical rhythm disorders, and lipid metabolism abnormalities. This test is recommended for individuals with a strong family history of premature heart disease, athletes undergoing pre-participation cardiac screening, and patients with unexplained cardiomyopathy or sudden cardiac arrest survivors. In the UAE, it is increasingly utilized by sports scientists and preventive cardiologists to stratify risk in apparently healthy individuals. The eight-week turnaround reflects the depth of genomic analysis and clinical annotation provided.
2. How long does it take to receive genetic cardiovascular mapping results in the UAE?
Results for the full cardiovascular genetic mapping panel are delivered within eight weeks from the date of sample collection at our Dubai laboratory. This comprehensive timeline encompasses DNA extraction, chromosomal microarray hybridization, SNP genotype calling, bioinformatic annotation against the latest ClinVar and gnomAD databases, and final clinical report generation by a board-certified molecular geneticist. Patients receive telephonic post-test clinical guidance from a DHA-licensed medical geneticist upon report availability. Expedited processing is not available for this panel due to the analytical rigor required.
3. Is genetic mapping for cardiovascular disorders covered by insurance and regulated in the UAE?
Many UAE-based insurance providers now offer coverage for cardiovascular genetic mapping when the test is medically indicated by a DHA-licensed specialist and pre-authorized through the insurer's prior-approval pathway. Coverage eligibility typically requires documentation of a first-degree relative with premature cardiovascular disease, a personal history of unexplained cardiac events, or participation in elite athletic programs. Our team provides direct billing verification via WhatsApp at +971 54 548 8731. All genetic testing in the UAE is regulated under Federal Decree-Law No. 45 of 2021 on Personal Data Protection and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring your genomic data remains confidential and encrypted.
4. What sample type is required for cardiovascular genetic mapping and how is collection arranged?
The test requires 3 mL of whole blood collected in a lavender top EDTA tube. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM across all seven emirates with temperature-controlled cold-chain logistics. Our DHA-licensed phlebotomy team coordinates directly with you to schedule a convenient appointment. A completed and signed Genome Mapping Consent Form (Form 26) is mandatory at the time of collection. Samples received without this form will be rejected and require recollection.
UAE Regulatory & Data Privacy Adherence
This laboratory service operates under the full regulatory framework of the United Arab Emirates. All genetic testing is conducted in strict compliance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — All genomic data is classified as sensitive personal data, stored on encrypted servers within UAE territory, and never shared with third parties without explicit, revocable consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — Governs the electronic processing, storage, and transmission of health data including genetic information.
- Federal Decree-Law No. 4 of 2016 on Medical Liability — Ensures patient consent, clinical validity, and safety standards for all diagnostic procedures including genetic testing.
- DHA Facility License 1143 — Issued by Dubai Health Authority, affirming compliance with clinical laboratory standards at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
- ISO 9001:2015 Certification — Internationally accredited quality management system covering all pre-analytical, analytical, and post-analytical phases.
Genetic data is never sold, de-identified without consent, or transferred outside UAE jurisdiction except where explicitly authorized by the data subject under PDPL safeguards.
Clinical & Logistical Metadata
| Test Name | Genetic Mapping for Cardiovascular Disorders |
| Price (AED) | 2,300 AED |
| Turnaround Time | 8 Weeks (Comprehensive Genomic Analysis, Annotation & Clinical Report) |
| Sample Type / Matrix | 3 mL Whole Blood (Lavender Top EDTA Tube) |
| Methodology Used | High-Density SNP Genotyping via Chromosomal Microarray + LC-MS/MS Validation |
| ICD-10-CM Code | I25.10, Z84.1, I42.8 |
| LOINC Code | 53039-4 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
Schedule Your Cardiovascular Genetic Mapping – UAE-Wide Home Collection
Our DHA-licensed mobile phlebotomy team serves all seven emirates with ISO-certified cold-chain logistics. Collection available daily from 8:00 AM to 11:00 PM. Same-day collection slots are subject to availability. A completed Genome Mapping Consent Form (Form 26) is mandatory at the time of collection.
DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians